ClinicalTrials.gg
TerminatedNCT04895410Updated Mar 6, 2023

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

A Phase 1 interventional study of Lemzoparlimab and Dexamethasone in Multiple Myeloma, sponsored by AbbVie. Terminated at 32 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Strategic considerations

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Multiple Myeloma by AbbVie — 7 open to participants now, 17 under way, 5 of them phase 3. Multiple Myeloma · AbbVie.

Enrollment
32nd of 39
8 · median 84
Started
2022
with 3 others
Phase 1
18 of 40
3 open now
Registered
28th of 40
by date

Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 32nd largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2022, is one of 18 in phase 1, and was the 28th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by AbbVie, or all of them as a file.
02

Study summary

Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with MM when given with or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events and change in disease activity will be assessed.

Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM. Study doctors put the participants in groups called treatment arms. Two different dose levels of lemzoparlimab will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of lemzoparlimab, followed by a dose expansion phase to confirm the dose. Approximately 163 adult participants with R/R MM will be enrolled in the study in approximately 60 sites worldwide.

In the Dose Escalation arms, participants will receive intravenous (IV) lemzoparlimab with or without dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or subcutaneous (SC) daratumumab in 28-day cycles. In the Dose Expansion arms, participants will receive lemzoparlimab (IV) alone or with dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or daratumumab (SC) in 28-day cycles.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests and side effects.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Lemzoparlimab
  • ABBV-IMAB-TJC4
  • Relapsed or refractory multiple myeloma (R/R MM)
  • Cancer
  • TJ011133
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria.

    • Relapsed defined as previously treated myeloma that progresses and requires initiation of salvage therapy, but does not meet criteria for refractory myeloma.
    • Refractory defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy, or progresses within 60 days of last therapy.
  • per the protocol within 28 days prior to enrollment.
  • Arm A - Lemzoparlimab with or without Dexamethasone

    • For Both Escalation and Expansion Phase, participant must have refractory to 3 of anti-myeloma treatments, as outlined in the protocol.
  • Arm B - Lemzoparlimab + Pomalidomide-Dexamethasone

    • For Escalation Phase - Participant must have received at least 3 prior lines of therapy, as outlined in the protocol.
    • For Expansion Phase- Participant must have received at least 2 prior line of therapy, as outlined in the protocol.
  • Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone

    • For Escalation Phase- Participant must have received at least 3 prior lines of therapy as outlined in the protocol.
    • For Expansion Phase- Participant must have received at least 1 prior line of therapy.
  • Arm D - Lemzoparlimab + Daratumumab-Dexamethasone -- For Both Escalation and Expansion Phase - Participant must: --- Have received at least 3 prior lines of therapy, as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Arm B - Lemzoparlimab + Pomalidomide-Dexamethasone

    • For Both Escalation and Expansion Phase participant must have had no prior treatment with pomalidomide.
  • Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone

    • For Both Escalation and Expansion Phase - prior treatment with carfilzomib.
  • Arm D - Lemzoparlimab + Daratumumab-Dexamethasone

    • For Both Escalation and Expansion Phase - prior treatment with daratumumab or other anti-CD38 therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Lemzoparlimab

    Participants will receive lemzoparlimab in 28 day cycles.

    Biological: Lemzoparlimab

  • Experimental
    Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone

    Participants will receive lemzoparlimab + pomalidomide + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone

    Participants will receive lemzoparlimab + carfilzomib + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone

    Participants will receive lemzoparlimab + daratumumab + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Biological: Daratumumab

  • Experimental
    Dose Expansion: Lemzoparlimab

    Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion in 28 day cycles.

    Biological: Lemzoparlimab

  • Experimental
    Dose Expansion: Lemzoparlimab + Dexamethasone

    Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone

  • Experimental
    Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone

    Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Pomalidomide

  • Experimental
    Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone

    Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Drug: Carfilzomib

  • Experimental
    Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone

    Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.

    Biological: Lemzoparlimab · Drug: Dexamethasone · Biological: Daratumumab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

    DLT events as described in the protocol will be assessed.

    Time frame: Up to 28 days after study drug administration

Secondary outcomes

  1. Percentage of Participants Achieving Best Overall Response of Documented Partial Response (PR) or Better

    Best overall response is defined as achieving documented PR or better at two consecutive disease assessments during the study, according to International Myeloma Working Group (IMWG) 2016 criteria.

    Time frame: Up to approximately 2 years

  2. Progression Free Survival (PFS)

    PFS is defined as the time from the first dose of study drug to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  3. Duration of Response (DOR)

    DOR is defined as the time from first documented response (PR or better) to the first documented PD or death due to MM, whichever occurs first.

    Time frame: Up to approximately 2 years

  4. Time to Progression (TTP)

    TTP is defined as the time from the first dose of study drug to the first documented PD or death due to MM, whichever occurs first.

    Time frame: Up to approximately 2 years

07

Study locations

32 sites
  • Sylvester Comprehensive Cancer Center /ID# 228817
    Miami, Florida 33136-1002, United States
  • Moffitt Cancer Center /ID# 229939
    Tampa, Florida 33612-9416, United States
  • Norton Cancer Institute - St Matthews /ID# 229319
    Louisville, Kentucky 40207, United States
  • Tulane Cancer Center Clinic /ID# 229832
    New Orleans, Louisiana 70112, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System /ID# 230341
    Detroit, Michigan 48202, United States
  • Rutgers Cancer Institute of New Jersey /ID# 230174
    New Brunswick, New Jersey 08901, United States
  • Columbia University Medical Center /ID# 229971
    New York, New York 10032-3729, United States
  • Duke University Hospital /ID# 229564
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Health /ID# 229996
    Winston-Salem, North Carolina 27157-0001, United States
  • Perelman Center for Advanced Medicine - /ID# 228693
    Philadelphia, Pennsylvania 19104-5127, United States
  • University of Virginia /ID# 229396
    Charlottesville, Virginia 22908, United States
  • The Queen Elizabeth Hospital /ID# 229345
    Woodville South, South Australia 5011, Australia
  • Alfred Health /ID# 229347
    Melbourne, Victoria 3004, Australia
  • HCL - Hôpital Lyon Sud /ID# 229834
    Pierre Benite CEDEX, Auvergne-Rhone-Alpes 69495, France
  • CHU de Nantes, Hotel Dieu -HME /ID# 228559
    Nantes, Pays-de-la-Loire 44000, France
  • CHU Poitiers - La milétrie /ID# 229833
    Poitiers, Poitou-Charentes 86000, France
  • Hopital Henri Mondor /ID# 228562
    Creteil, 94000, France
  • Asklepios Klinik Altona /ID# 229143
    Hamburg, 22763, Germany
  • The Chaim Sheba Medical Center /ID# 229483
    Ramat Gan, Tel-Aviv 5265601, Israel
  • Tel Aviv Sourasky Medical Center /ID# 229478
    Tel Aviv-Yafo, Tel-Aviv 6423906, Israel
  • Rambam Health Care Campus /ID# 229485
    Haifa, 3109601, Israel
  • Hadassah Medical Center-Hebrew University /ID# 229477
    Jerusalem, 91120, Israel
  • Meir Medical Center /ID# 229480
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center /ID# 229488
    Petakh Tikva, 4941492, Israel
  • University Hospital Kyoto Prefectural University of Medicine /ID# 241833
    Kyoto-shi, Kyoto 602-8566, Japan
  • Hospital Clínico Universitario de Santiago-CHUS /ID# 229356
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Unversitario Marques de Valdecilla /ID# 229354
    Santander, Cantabria 39008, Spain
  • Hospital Parc de Salut del Mar /ID# 229371
    Barcelona, 08003, Spain
  • Hospital Santa Creu i Sant Pau /ID# 229369
    Barcelona, 08041, Spain
  • Hospital Universitario Reina Sofia /ID# 229388
    Cordoba, 14004, Spain
  • Hospital Universitario 12 de Octubre /ID# 229355
    Madrid, 28041, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jun 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 20, 2021
StartActual
Jan 17, 2022
Primary completionActual
Jun 24, 2022
CompletionActual
Jun 24, 2022
Last update
Mar 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04895410
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Jan 17, 2022
Primary completion
Jun 24, 2022
Completion
Jun 24, 2022
Last update
Mar 6, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemzoparlimab

Start the discussion